Stock Analysis on Net
Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Present Value of Free Cash Flow to Equity (FCFE)

Microsoft Excel

In discounted cash flow (DCF) valuation techniques the value of the stock is estimated based upon present value of some measure of cash flow. Free cash flow to equity (FCFE) is generally described as cash flows available to the equity holder after payments to debt holders and after allowing for expenditures to maintain the company asset base.

Intrinsic Stock Value (Valuation Summary)

Regeneron Pharmaceuticals Inc., free cash flow to equity (FCFE) forecast

US$ in thousands, except per share data

Microsoft Excel
Year Value FCFEt or Terminal value (TVt) Calculation Present value at 5.83%
01 FCFE0 3,875,400
1 FCFE1 4,836,843 = 3,875,400 × (1 + 24.81%) 4,570,415
2 FCFE2 5,758,116 = 4,836,843 × (1 + 19.05%) 5,141,238
3 FCFE3 6,523,087 = 5,758,116 × (1 + 13.29%) 5,503,439
4 FCFE4 7,013,833 = 6,523,087 × (1 + 7.52%) 5,591,522
5 FCFE5 7,137,370 = 7,013,833 × (1 + 1.76%) 5,376,585
5 Terminal value (TV5) 178,538,692 = 7,137,370 × (1 + 1.76%) ÷ (5.83% – 1.76%) 134,493,291
Intrinsic value of Regeneron Pharmaceuticals Inc. common stock 160,676,491
 
Intrinsic value of Regeneron Pharmaceuticals Inc. common stock (per share) $1,463.86
Current share price $883.20

Based on: 10-K (reporting date: 2023-12-31).

1 See details »

Disclaimer!
Valuation is based on standard assumptions. There may exist specific factors relevant to stock value and omitted here. In such a case, the real stock value may differ significantly form the estimated. If you want to use the estimated intrinsic stock value in investment decision making process, do so at your own risk.

Required Rate of Return (r)

Microsoft Excel
Assumptions
Rate of return on LT Treasury Composite1 RF 4.86%
Expected rate of return on market portfolio2 E(RM) 13.52%
Systematic risk of Regeneron Pharmaceuticals Inc. common stock βREGN 0.11
 
Required rate of return on Regeneron Pharmaceuticals Inc. common stock3 rREGN 5.83%

1 Unweighted average of bid yields on all outstanding fixed-coupon U.S. Treasury bonds neither due or callable in less than 10 years (risk-free rate of return proxy).

2 See details »

3 rREGN = RF + βREGN [E(RM) – RF]
= 4.86% + 0.11 [13.52% – 4.86%]
= 5.83%

FCFE Growth Rate (g)

FCFE growth rate (g) implied by PRAT model

Regeneron Pharmaceuticals Inc., PRAT model

Microsoft Excel
Average Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in thousands)
Net income 3,953,600 4,338,400 8,075,300 3,513,200 2,115,800
Revenues 13,117,200 12,172,900 16,071,700 8,497,100 7,863,400
Total assets 33,080,200 29,214,500 25,434,800 17,163,300 14,805,200
Stockholders’ equity 25,973,100 22,664,000 18,768,800 11,025,300 11,089,700
Financial Ratios
Retention rate1 1.00 1.00 1.00 1.00 1.00
Profit margin2 30.14% 35.64% 50.25% 41.35% 26.91%
Asset turnover3 0.40 0.42 0.63 0.50 0.53
Financial leverage4 1.27 1.29 1.36 1.56 1.34
Averages
Retention rate 1.00
Profit margin 36.86%
Asset turnover 0.49
Financial leverage 1.36
 
FCFE growth rate (g)5 24.81%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

2023 Calculations

1 Company does not pay dividends

2 Profit margin = 100 × Net income ÷ Revenues
= 100 × 3,953,600 ÷ 13,117,200
= 30.14%

3 Asset turnover = Revenues ÷ Total assets
= 13,117,200 ÷ 33,080,200
= 0.40

4 Financial leverage = Total assets ÷ Stockholders’ equity
= 33,080,200 ÷ 25,973,100
= 1.27

5 g = Retention rate × Profit margin × Asset turnover × Financial leverage
= 1.00 × 36.86% × 0.49 × 1.36
= 24.81%

FCFE growth rate (g) implied by single-stage model

g = 100 × (Equity market value0 × r – FCFE0) ÷ (Equity market value0 + FCFE0)
= 100 × (96,941,707 × 5.83% – 3,875,400) ÷ (96,941,707 + 3,875,400)
= 1.76%

where:
Equity market value0 = current market value of Regeneron Pharmaceuticals Inc. common stock (US$ in thousands)
FCFE0 = the last year Regeneron Pharmaceuticals Inc. free cash flow to equity (US$ in thousands)
r = required rate of return on Regeneron Pharmaceuticals Inc. common stock

FCFE growth rate (g) forecast

Regeneron Pharmaceuticals Inc., H-model

Microsoft Excel
Year Value gt
1 g1 24.81%
2 g2 19.05%
3 g3 13.29%
4 g4 7.52%
5 and thereafter g5 1.76%

where:
g1 is implied by PRAT model
g5 is implied by single-stage model
g2, g3 and g4 are calculated using linear interpoltion between g1 and g5

Calculations

g2 = g1 + (g5 – g1) × (2 – 1) ÷ (5 – 1)
= 24.81% + (1.76% – 24.81%) × (2 – 1) ÷ (5 – 1)
= 19.05%

g3 = g1 + (g5 – g1) × (3 – 1) ÷ (5 – 1)
= 24.81% + (1.76% – 24.81%) × (3 – 1) ÷ (5 – 1)
= 13.29%

g4 = g1 + (g5 – g1) × (4 – 1) ÷ (5 – 1)
= 24.81% + (1.76% – 24.81%) × (4 – 1) ÷ (5 – 1)
= 7.52%